Header Logo

Connection

John Harris to Male

This is a "connection" page, showing publications John Harris has written about Male.
Connection Strength

0.526
  1. Refat MA, Strassner JP, Frisoli ML, Rashighi M, Richmond J, Nada E, Saleh R, El-Hamd MA, Goldberg D, Mahmoud BH, Harris JE. Lesional CD8+ T-Cell Number Predicts Surgical Outcomes of Melanocyte-Keratinocyte Transplantation Surgery for Vitiligo. J Invest Dermatol. 2023 11; 143(11):2275-2282.e6.
    View in: PubMed
    Score: 0.053
  2. Fukuda K, Okamura K, Riding RL, Fan X, Afshari K, Haddadi NS, McCauley SM, Guney MH, Luban J, Funakoshi T, Yaguchi T, Kawakami Y, Khvorova A, Fitzgerald KA, Harris JE. AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma. J Exp Med. 2021 09 06; 218(9).
    View in: PubMed
    Score: 0.046
  3. Riding RL, Richmond JM, Fukuda K, Harris JE. Type I interferon signaling limits viral vector priming of CD8+ T cells during initiation of vitiligo and melanoma immunotherapy. Pigment Cell Melanoma Res. 2021 07; 34(4):683-695.
    View in: PubMed
    Score: 0.044
  4. Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, Butler K, Kuo F, Sun K, Ji T, Howell MD, Harris JE. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020 07 11; 396(10244):110-120.
    View in: PubMed
    Score: 0.043
  5. Tkachenko E, Refat MA, Balzano T, Maloney ME, Harris JE. Patient satisfaction and physician productivity in shared medical appointments for vitiligo. J Am Acad Dermatol. 2019 Nov; 81(5):1150-1156.
    View in: PubMed
    Score: 0.039
  6. Strassner JP, Rashighi M, Ahmed Refat M, Richmond JM, Harris JE. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J Am Acad Dermatol. 2017 May; 76(5):847-855.e5.
    View in: PubMed
    Score: 0.034
  7. Vanderweil SG, Amano S, Ko WC, Richmond JM, Kelley M, Senna MM, Pearson A, Chowdary S, Hartigan C, Barton B, Harris JE. A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo. J Am Acad Dermatol. 2017 Jan; 76(1):150-151.e3.
    View in: PubMed
    Score: 0.034
  8. Harris JE, Rashighi M, Nguyen N, Jabbari A, Ulerio G, Clynes R, Christiano AM, Mackay-Wiggan J. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol. 2016 Feb; 74(2):370-1.
    View in: PubMed
    Score: 0.031
  9. Harris JE. IFN-? in Vitiligo, Is It the Fuel or the Fire? Acta Derm Venereol. 2015 Jul; 95(6):643-4.
    View in: PubMed
    Score: 0.030
  10. Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su MW, Zhou Y, Deng A, Hunter CA, Luster AD, Harris JE. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014 Feb 12; 6(223):223ra23.
    View in: PubMed
    Score: 0.027
  11. Harris JE. Vitiligo and alopecia areata: apples and oranges? Exp Dermatol. 2013 Dec; 22(12):785-9.
    View in: PubMed
    Score: 0.027
  12. Patel A, Sener A, Lee SY. Reversed diastolic flow in a renal transplant due to ureteric obstruction from intraluminal blood clot. J Clin Ultrasound. 2022 May; 50(4):521-524.
    View in: PubMed
    Score: 0.023
  13. Harris JE, Seykora JT, Lee RA. Renbok phenomenon and contact sensitization in a patient with alopecia universalis. Arch Dermatol. 2010 Apr; 146(4):422-5.
    View in: PubMed
    Score: 0.021
  14. Harris JE, Sutton DA, Rubin A, Wickes B, De Hoog GS, Kovarik C. Exophiala spinifera as a cause of cutaneous phaeohyphomycosis: case study and review of the literature. Med Mycol. 2009 Feb; 47(1):87-93.
    View in: PubMed
    Score: 0.019
  15. Bibeau K, Ezzedine K, Harris JE, van Geel N, Grimes P, Parsad D, Tulpule M, Gardner J, Valle Y, Tlhong Matewa G, LaFiura C, Lindley A, Ren H, Hamzavi IH. Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo: Findings From the Global VALIANT Study. JAMA Dermatol. 2023 10 01; 159(10):1124-1128.
    View in: PubMed
    Score: 0.013
  16. Damsky W, Patel D, Garelli CJ, Garg M, Wang A, Dresser K, Deng A, Harris JE, Richmond J, King B. Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea. J Invest Dermatol. 2020 07; 140(7):1446-1449.e4.
    View in: PubMed
    Score: 0.010
  17. Mande P, Zirak B, Ko WC, Taravati K, Bride KL, Brodeur TY, Deng A, Dresser K, Jiang Z, Ettinger R, Fitzgerald KA, Rosenblum MD, Harris JE, Marshak-Rothstein A. Fas ligand promotes an inducible TLR-dependent model of cutaneous lupus-like inflammation. J Clin Invest. 2018 07 02; 128(7):2966-2978.
    View in: PubMed
    Score: 0.009
  18. Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017 Oct; 77(4):675-682.e1.
    View in: PubMed
    Score: 0.009
  19. Li JL, Lim CH, Tay FW, Goh CC, Devi S, Malleret B, Lee B, Bakocevic N, Chong SZ, Evrard M, Tanizaki H, Lim HY, Russell B, Renia L, Zolezzi F, Poidinger M, Angeli V, St John AL, Harris JE, Tey HL, Tan SM, Kabashima K, Weninger W, Larbi A, Ng LG. Neutrophils Self-Regulate Immune Complex-Mediated Cutaneous Inflammation through CXCL2. J Invest Dermatol. 2016 Feb; 136(2):416-424.
    View in: PubMed
    Score: 0.008
  20. Ram?n HE, Cejas PJ, LaRosa D, Rahman A, Harris JE, Zhang J, Hunter C, Choi Y, Turka LA. EGR-2 is not required for in vivo CD4 T cell mediated immune responses. PLoS One. 2010 Sep 23; 5(9):e12904.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.